Discounted by less than 20% to sprint Hong Kong stocks Hengrui Medicine (600276.SH) is expected to be listed on May 23.

According to the Intelligent Finance and Economics APP, on May 15, 2025, the leading innovative pharmaceutical company Hansoh Pharma (600276.SH) officially launched the global public offering of H shares, planning to issue 224,519,800 H shares (assuming the exercise of the over-allotment option and the adjustment option for the sales volume is not used), with 5.5% (12,348,600 shares) for public sale in Hong Kong and 94.5% (212,171,200 shares) for international placement, with an offering price range of HK$41.45-44.05 per share. If the over-allotment option and adjustment option for the sales volume are fully exercised, the maximum number of H shares issued could reach 296,927,200 shares, raising up to HK$13.08 billion. This means that Hansoh Pharma's fundraising amount will become the highest among Hong Kong-listed pharmaceutical company IPOs in the past five years. It is understood that the Hong Kong public offering of Hansoh Pharma's H shares will end on May 20, 2025, with the final offering price expected to be determined before May 22 (inclusive), and the earliest listing on the Hong Kong Stock Exchange Main Board may occur on May 23. The offering is jointly sponsored by Morgan Stanley, Citigroup, and Huatai International.